RealSeq Biosciences

Executive Summary

RealSeq Biosciences is a San Diego-based biotechnology company pioneering RNA fragmentomics for next-generation diagnostics. Its proprietary RiboMarker® platform enables the discovery of novel RNA biomarkers from fragments that conventional sequencing methods miss, unlocking diagnostic potential in oncology, infectious disease, and agriculture. Founded in 2018, the company is privately held and has not disclosed funding, valuation, or revenue, indicating an early-stage profile. By focusing on previously undetectable RNA fragments, RealSeq aims to improve sensitivity and specificity in liquid biopsy and other non-invasive tests, addressing critical gaps in early disease detection and monitoring. The platform's versatility across multiple therapeutic areas positions it as a potentially disruptive tool in the precision diagnostics market, though it faces significant technical and commercial validation hurdles.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round65% success
• Q2 2027Research Partnership with Major Cancer Center50% success
• Q3 2027Launch of First Commercial Diagnostic Test30% success